Possis Medical answers FDA questions
This article was originally published in Clinica
Executive Summary
Possis Medical says it has submitted supplementary data on its AngioJet thrombectomy catheter to the US FDA. Possis submitted a 510(k) for peripheral artery applications in March, but only used data from the first 86 patients out of a full cohort of 130. However, the FDA insisted that it should receive either the full data set or proof that 86 patients were sufficient to demonstrate the safety of AngioJet (see Clinica No 712, p 19). Possis spokesman Robert Dutcher says the company now has clinical data (which compares AngioJet to the Fogarty embolectomy catheter) for all 130 patients and has submitted it to the agency.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.